Article Text

Download PDFPDF

Highlights from this issue
  1. Keith Barton1,
  2. James Chodosh2,
  3. Jost B Jonas, Editors in chief1,2,3
  1. 1 Moorfields Eye Hospital, London, UK
  2. 2 Department of Ophthalmology, Massachusetts Eye and Ear Infirmary Howe Laboratory Harvard Medical School, Boston, Massachusetts, USA
  3. 3 Department of Ophthalmology, Ruprecht-Karls-University Heidelberg, Seegartenklinik Heidelberg, Mannheim, Germany
  1. Correspondence to Keith Barton, Moorfields Eye Hospital, London E1V 2PD, UK; BJO{at}

Statistics from

Neuroretinal atrophy following resolution of macular oedema in retinal vein occlusion (see page 36)

In this study of patients with retinal vein occlusion treated with ranibizumab, significant neuroretinal thinning was observed after the resolution of macular oedema in 11% of eyes. The presence of retinal atrophy was not associated with poorer visual acuity.

Type 3 neovascularisation: long-term analysis of visual acuity and optical coherence tomography anatomical outcomes (see page 43)

Increased age, male gender and lower baseline vision were identified as baseline predictors of poor visual outcomes in eyes with type 3 neovascularisation. Greater central outer retinal atrophy was associated with worse long-term visual outcomes.

Acute retinal toxicity associated with a mixture of perfluorooctane and perfluorohexyloctane: failure of another indirect cytotoxicity analysis (see page 49)

A batch of Bio Octane Plus containing perfluorooctane and perfluorohexyloctane exhibited clinical and experimental toxicity. ISO International Standards protocols used to determine the toxicity of intraocular medical devices failed and should be revised.

Baseline choroidal thickness as a short-term predictor of visual acuity improvement following antivascular endothelial growth factor therapy in branch retinal vein occlusion (see page 55)

Branch retinal vein occlusion eyes with a higher baseline choroidal thickness may be more likely to achieve functional response (best corrected visual acuity gain ≥2 lines) following antivascular endothelial …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles